NEW YORK, December 28, 2016 /PRNewswire/ --
Today, Stock-Callers.com looks at the Biotech segment which is engaged in the development of pharmaceuticals, pest-resistant crops, and biofuels, among other products. Firms in this industry primarily use living organisms or molecular and cellular techniques to develop products that are used in agriculture, food, industrial, and medicine production. Under evaluation are Eleven Biotherapeutics Inc. (NASDAQ: EBIO), Illumina Inc. (NASDAQ: ILMN), Sangamo Biosciences Inc. (NASDAQ: SGMO), and CytRx Corp. (NASDAQ: CYTR). Learn more about these stocks by downloading their comprehensive and free reports at:
At the close on Tuesday, shares in Cambridge, Massachusetts-based Eleven Biotherapeutics Inc. rose 3.55%, ending the day at $2.04 with a total trading volume of 481,797 shares. The stock is trading below its 50-day moving average by 6.82%. Shares of the Company, which engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the US, have a Relative Strength Index (RSI) of 46.76.
On November 14th, 2016, Eleven Biotherapeutics reported that revenue was $28.7 million for Q3 2016 compared to $0.1 million for Q3 2015. The increase was due to revenue recognized from the License Agreement with Roche. The Company's net income was $19.5 million, or $0.95 per basic share and $0.91 per diluted share, for Q3 2016 as compared to a net loss of $9.7 million, or $0.50 per basic and diluted share, for Q3 2015. Cash and cash equivalents were $30.7 million as of September 30th, 2016. EBIO complete research report is just a click away and free at:
Shares in San Diego, California headquartered Illumina Inc. ended the day 0.15% higher at $128.94 with a total trading volume of 539,240 shares. The stock is trading below its 50-day moving average by 3.76%. Shares of the Company, which provides sequencing and array-based solutions for genetic analysis, have an RSI of 47.60.
On December 7th, 2016, Illumina announced the appointment of Sam A. Samad, Senior Vice President and Chief Financial Officer. He will join the Company on January 06th, 2017. Sam will be responsible for the Company's finance, accounting, investor relations, internal audit, and treasury functions. He joins Illumina from Cardinal Health where he held several senior leadership positions including most recently Senior Vice President and Corporate Treasurer, with leadership responsibility for Cardinal Health's China business. Sam holds a BBA degree from the American University of Beirut in Lebanon and an MBA from McMaster University in Hamilton, Canada.
On December 7th, 2016, research firm Morgan Stanley reiterated its 'Underweight' rating on the Company's stock with a decrease of the target price from $115 a share to $100 a share. The complimentary report on ILMN can be downloaded at:
On Tuesday, shares in Richmond, California headquartered Sangamo Biosciences Inc. finished 3.23% lower at $3.00. A total volume of 842,029 shares was traded. The stock is trading below its 50-day moving average by 15.42%. Additionally, shares of Sangamo Biosciences, which focuses on the research, development, and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation, have an RSI of 43.06.
On November 30th, 2016, Sangamo BioSciences announced that its collaborative zinc finger nuclease (ZFN)-mediated genome editing program for hemoglobinopathies will transfer to Bioverativ. In 2014, Sangamo and Biogen entered into an exclusive worldwide research, development, and commercialization collaboration and license agreement under which both companies agreed to develop and commercialize therapeutic genome editing products for the potential treatment of two inherited blood disorders, sickle cell disease and beta-thalassemia. Bioverativ, the planned spin-off of Biogen's hemophilia business, is on track to launch as an independent, publicly-traded biotechnology company in early 2017. Sign up for your complimentary research report on SGMO at:
Los Angeles, California headquartered CytRx Corp.'s shares recorded a trading volume of 1.66 million shares at the end of yesterday's session, which was higher than their three months average volume of 1.23 million shares. The stock closed the day flat at $0.39. The Company's shares are trading below their 50-day moving average by 20.47%. Additionally, shares of CytRx, which operates as a biopharmaceutical research and development company specializing in oncology, have an RSI of 35.54.
On December 13th, 2016, CytRx announced that it has entered into securities purchase agreements with existing institutional investors to purchase shares of the Company's common stock at a purchase price of $0.42 per share in a registered direct offering with gross proceeds of $8.1 million. To the extent that the purchase of shares of common stock would result in beneficial ownership above 4.99%, an investor may elect to purchase shares of its Series B convertible preferred stock in lieu of common stock. Each share of preferred stock has a conversion price of $0.42 and no dividend rights. Get free access to your research report on CYTR at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA